Efgartigimod Alfa + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Optic Neuritis
Conditions
Optic Neuritis
Trial Timeline
Aug 12, 2025 → Jul 1, 2027
NCT ID
NCT06453694About Efgartigimod Alfa + Placebo
Efgartigimod Alfa + Placebo is a phase 2 stage product being developed by Argenx for Optic Neuritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06453694. Target conditions include Optic Neuritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06453694 | Phase 2 | Recruiting |
Competing Products
20 competing products in Optic Neuritis